Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
881-900 of 1,694 trials

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Non-Small Cell Lung Cancer: Sotorasib Treatment Study

We are studying the effects of Sotorasib in patients with non-operable non-small cell lung cancer who have a KRAS mutation. The goal is to see if this treatment improves survival and response rates compared to standard options.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cholestatic Pruritus: Maralixibat Study

We are testing a new medication, maralixibat, for individuals with cholestatic pruritus to see if it can reduce itching and lower bile acid levels in the blood.

Cholestatic PruritusConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteDermatologyHepatology

Myelofibrosis: Selinexor Treatment Study

We are studying the effects of selinexor in patients with myelofibrosis who haven't been treated with JAK inhibitors. The goal is to see if it helps improve symptoms and overall health.

MyelofibrosisModerate ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Oral Propranolol for Preventing Eye Issues in Premature Infants

We are studying whether oral propranolol can help extremely preterm infants lower their risk of developing threshold retinopathy of prematurity. This research aims to improve safety and reduce the need for additional treatments.

Retinopathy of Prematurity>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteOphthalmologyPediatrics

Crohn's Disease: EXL01 for Post-Surgery Recurrence Prevention

We are studying whether EXL01 can help prevent the return of Crohn's disease in patients after surgery. This trial compares its effects to a placebo to assess safety and effectiveness.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

Colchicine for Knee and Hip Osteoarthritis

We are studying whether colchicine can help reduce the need for knee or hip replacements in people with osteoarthritis. The trial also looks at its effects on pain, physical function, and overall quality of life.

Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyRheumatology

Dental Implant Surgery: Antibiotics Study

We are investigating whether taking antibiotics helps patients recover better after dental implant surgery with bone regeneration and sinus elevation. This study compares the effects of antibiotics to a placebo on patient outcomes.

Implant Surgery with Guided Bone Regeneration6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesGynecology and ObstetricsInfectious DiseasesOrthopedics and TraumatologyOtolaryngology

NRAS Mutant Melanoma: Naporafenib + Trametinib Study

We are testing a new combination therapy for patients with previously treated NRAS mutant cutaneous melanoma. The goal is to see if it works better than standard treatment options in improving survival and managing the disease.

Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Ulcerative Colitis: Filgotinib for Kids and Teens

We are studying the effects of filgotinib in children and teenagers with moderately to severely active ulcerative colitis. The trial aims to see if it helps achieve remission and improves quality of life.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Fibrodysplasia Ossificans Progressiva: Fidrisertib Study

We are studying a new oral medication for people with fibrodysplasia ossificans progressiva to see if it can help prevent new bone growth and improve overall health. This trial includes both children and adults to evaluate its safety and effectiveness.

Fibrodysplasia Ossificans ProgressivaEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurology

Fanconi Anemia: Afatinib for Advanced Squamous Cell Carcinoma

We are studying whether Afatinib can help patients with Fanconi anemia who have advanced squamous cell carcinoma in the head and neck. The trial will assess its effectiveness and safety compared to current treatment options.

Advanced Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Chronic Myeloid Leukemia: Olverembatinib Study

We are testing a new drug, Olverembatinib, for patients with Chronic Phase Chronic Myeloid Leukemia. The study aims to see if it works better than the current treatment, Bosutinib, especially for those with a specific mutation.

Chronic Myeloid Leukemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: Alisertib with Hormone Therapy

We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Posaconazole for Fungal Infection Prevention in Stem Cell Transplant Patients

We are studying whether posaconazole can effectively prevent fungal infections in patients receiving stem cell transplants. This research aims to understand how well the medication works and its impact on patient recovery.

Healthy Participants>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

HIV Research: Topiramate Treatment

We are investigating whether topiramate can help activate hidden HIV in people on antiretroviral therapy. The study also examines the safety of this medication and how various factors may influence its effects.

HIV-1 Infection≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Advanced Solid Tumors: ART0380 Oral Treatment

We are studying the safety and effectiveness of the oral medication ART0380 for patients with advanced or metastatic solid tumors. This includes testing it alone and in combination with other drugs to see how well it works.

Advanced or Metastatic Solid TumoursSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Myelofibrosis: Tasquinimod Treatment Study

We are studying tasquinimod in patients with myelofibrosis who are not responding to current treatments. The goal is to see if it can safely reduce spleen size and improve symptoms.

Myelofibrosis3-6 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology